Listed

American Vanguard Corp: Form 10-Q for the period ended Mar 31, 2020

Filed with the SEC on May 11, 2020 and accepted by EDGAR at May 11, 2020, 16:21 ET.

Share

Management's discussion and analysis

As filed, 25,196 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

FORWARD-LOOKING STATEMENTS/RISK FACTORS:

The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company’s operations, future results and prospects. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and other factors. In connection with the Private Securities Litigation Reform Act of 1995, the Company provides the following cautionary statements identifying important factors which, among other things, could cause the actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire Report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources; general business regulations, including taxes and other risks as detailed from time-to-time in the Company’s reports and filings filed with the U.S. Securities and Exchange Commission (the “SEC”). It is not possible to foresee or identify all such factors. For more detailed information, refer to Item 1A., Risk factors and Item 7A., Quantitative and Qualitative Disclosures about Market Risk, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.

MANAGEMENT OVERVIEW

The Company’s Operations in the Context of the COVID-19 Pandemic

In March 2020, the World Health Organization categorized the novel coronavirus (COVID-19) as a pandemic, and it continues to spread across the world. To limit the spread of the contagion, governments have taken various actions to slow and otherwise control the spread of the pandemic, including the issuance of stay-at-home orders, social distancing guidelines and border restrictions. At its outset, the Company took swift action to understand, contain and mitigate the risks posed by this pandemic. Specifically, we formed the Pandemic Work Group with a mission to ensure the health and safety of the workforce while ensuring continuity of the business. In the workplace, we have designed and implemented protocols for social distancing, made provisions for the workforce to work remotely where possible, and established quarantine policies for those who present COVID-like symptom or may have been in touch with those who have. Further, the group keeps current with local, state, federal and international laws and restrictions that could affect the business; provides real-time information to the workforce; and draws from political commentary and news statements concrete directions on how best to continue operations. We have also prepared contingency plans to permit the continued operation of our factories, in the event that there are critical staffing issues due to attrition. In addition, in April 2020, we amended our credit facility to support future working capital needs (see note 10). Further, we continuously monitor supply chain, transport, logistics and border closures and have reached out to third parties to make clear that we are continuing to operate, that we have our own policies relating to health (e.g., no third party visitors, no face-to-face meetings) and are committed to compliance with COVID-19 policies of our business partners. Our CEO and the leader of the Pandemic Work Group is holding weekly “state of the company” calls with the functional heads of our businesses across the globe to ensure that our information is shared in a timely manner and that our direction is clear.

It is important to understand that under applicable federal guidelines (at https://www.cisa.gov), the Company is part of the nation’s “critical infrastructure” and falls within three of the 16 sectors that are specially permitted to operate: “Food and Agriculture” sector (engaged in “the production of chemicals and other substances used by the food and agriculture industry, including pesticides, herbicides etc.”), the “Chemical” sector (supporting the operation . . . of facilities (particularly those with high risk chemicals . . . whose work cannot be done remotely and requires the presence of highly trained personnel to ensure safe operations”) and the “Public Works and Infrastructure Support Services” sector (in support of exterminators, landscapers and others who provide services to residences and businesses). In issuing guidance on Coronavirus, President Trump said, “If you work in a critical infrastructure industry, as defined by the Department of Homeland Security, such as healthcare services and pharmaceutical and food supply, you have a special responsibility to maintain your normal work schedule [emphasis added].” We have found that state COVID-19 orders and, indeed, even those of countries in which the outbreak has been most pronounced (e.g., Italy), have consistently excepted food supply as an area essential to the survival of its populations and, as such, had given special permission to companies, such as ours, to continue to operate during the pandemic.

In keeping with our charge to operate as an essential business and by virtue of our efforts to contain and mitigate the risks posed by the pandemic, we have been able to manage our business with minimal impact during the reporting period.

Overview of the Company’s Performance

The Company’s overall operating results for the first three months of 2020 declined as compared with those of the same period of 2019. Net sales were down about 4% ($95,962 compared to $99,676) and gross profit was down 8% ($38,381 v. $41,702). Gross margin declined to 40% from 42% of net sales, and operating expenses rose by approximately 5% ($36,545 v. $34,800). Net income ended at $520, as compared to $3,906 for the same period of 2019.

On a consolidated basis, with domestic sales at or near flat and international sales down by about 9%, overall net sales were down by about 4% (or $3,714). While cost of sales were flat on an absolute basis, as a percent of net sales, they rose from 58% to 60%. These factors, taken together, yielded a decline in gross profit of about $3,321. In the first quarter of 2020 operating expenses increased by about $1,746, due largely to unfavorable foreign currency transaction effects (mainly from Brazil and partially offset by Mexico), and the fact that the Company was able to record a gain from accounting for deferred purchase price consideration in first quarter of 2019 that was not repeated in 2020. Consequently, operating income for the period decreased by approximately $5,000. After slightly lower interest rates and a higher; overall effective tax rate (offset by beneficial discrete items), net income for the period declined to $520. Details on our financial performance are set forth below.

RESULTS OF OPERATIONS

Quarter Ended March 31:

Net sales: For the three months ended March 31, 2020 2019 Change % Change
US crop $50,362 $50,270 $92 0%
US non-crop 10,993 11,267 (274) -2%
Total US 61,355 61,537 (182) 0%
International 34,607 38,139 (3,532) -9%
Total net sales: $95,962 $99,676 $(3,714) -4%
Cost of sales:
US crop $26,117 $26,448 $(331) -1%
US non-crop 6,274 5,421 853 16%
Total US 32,391 31,869 522 2%
International 25,190 26,105 (915) -4%
Total cost of sales: $57,581 $57,974 $(393) -1%
Gross profit:
US crop $24,245 $23,822 $423 2%
US non-crop 4,719 5,846 (1,127) -19%
Total US 28,964 29,668 (704) -2%
International 9,417 12,034 (2,617) -22%
Total gross profit: $38,381 $41,702 $(3,321) -8%
Gross margin:
US crop 48% 47%
US non-crop 43% 52%
Total US 47% 48%
International 27% 32%
Gross margin: 40% 42%

Our domestic crop business recorded net sales that were about equivalent to those of first quarter 2019 ($50,362 v. $50,270). When viewed by type of product and crop, sales were mixed. Further, in general, during the first quarter, we saw a very careful procurement pattern in the domestic market, as low crop commodity prices and concerns about near-term demand from Asia caused growers and retailers to purchase crop protection inputs at a very cautious and deliberate pace. Soil fumigants posted a strong performance as drier weather conditions in California and the Pacific Northwest facilitated more widespread product application than had been the case in the first quarter of 2019. With respect to our corn products, net sales of our corn soil insecticides, including Aztec®, SmartChoice® and Force®, were flat during the quarter, while our Impact® herbicide, which continues to exhibit strong brand value, generated increased sales. Soybean products, such as Scepter® and our recently acquired post-emergent products (e.g., Hornet® and Python®), added a strong upside, as compared to the same quarter in 2019. By contrast, with a 10 percent drop in planted cotton acres (relating to lower commodity prices), we experienced a drop in net sales of Bidrin® and bifenthrin products. We also saw a decrease in sales of our NAA plant growth regulator which is used primarily on tree nuts and pome fruits; this decrease arose in large part from timing of orders by certain of our larger customers.

Cost of sales within the domestic crop business were flat as compared to the first quarter of 2019, while gross profit rose by about 1% (from $23,822 to $24,245). This improvement rose from increased sales of higher margin products, such as soil fumigants and soybean herbicides.

Our domestic non-crop business showed decreased net sales (down about 2% to $10,993 from $11,267) quarter-over-quarter. In this category, our Dibrom® mosquito adulticide sales declined, influenced by timing shifts in customer procurement. In addition, license fees for our Envance essential oil technology were reduced as compared to first quarter of last year; we expect to recognize additional royalties during the later quarters of 2020. Offsetting these declines, we recorded sales under a new cost recovery tolling contract and improved net sales from our nursery and ornamental business, as demand for homeowner garden and landscape products in big box stores remained strong in spite of stay-at-home restrictions at retail locations.

Cost of sales within the domestic non-crop business rose by about 16% (from $5,421 to $6,274) quarter-over-quarter. This increase was entirely due to a supply agreement with a third party for certain newly acquired products that we are planning to produce internally in the future. Gross profit for domestic non-crop decreased by 19% (from $5,846 in 2019 to $4,719 in 2020) due primarily to lower license fees in our natural oil business.

Net sales of our international businesses were down by about 9% during the period ($34,607 in 2020 v. $38,139 in 2019). Several factors contributed to this result. In Europe, sales of our Mocap® insecticide dropped sharply in connection with the phase-out of that product following the cancellation of its registration in the EU. Sales performance was flat in Central America with stronger results from a rotation in the use of our nematicides in pineapple plantations, offset by consolidation by certain suppliers in that region and logistical difficulties arising from the pandemic in both Honduras and Panama. Mexico posted strongly improved sales with increased demand for granular insecticides and bromacil herbicides, coupled with higher soil fumigant sales for use on high-value vegetable crops. In Brazil, net sales declined by about 20% due to lower disease pressure in soybeans (thus reducing demand for our fungicide products), portfolio streamlining (to optimize our sales resources) and delays in procurement arising from economic uncertainty. The performances of our Brazilian and Mexican businesses were further affected by a devaluation in the Brazilian Real and the Mexican Peso. The average exchange rate of the Brazilian Real and the Mexican Peso decreased by approximately 15% and 3% for the period ended March 31, 2020 compared to the same period in the prior year.

Cost of sales in our international business decreased by 4% (from $26,105 in 2019 to $25,190 in 2020) primarily driven by mix and currency changes. Gross profit for the international businesses dropped by about 22% (from $12,034 in 2019 to $9,417 in 2020). This decrease arose from several factors. Sales of certain high margin products, including Mocap (as mentioned above), Impact and pest strips, decreased. In addition, while sales of our Assure II® products into Canada increased, the cost of goods rose significantly. Further, we experienced higher sales of low-margin products from our business in Australia.

On a consolidated basis, gross profit for the first quarter of 2020 decreased by 8% (from $41,702 in 2019 to $38,381 in 2020). The change in mix described above had the impact of reducing gross margin percentage by approximately 2% and included a balanced factory performance quarter-over-quarter. Overall gross margin percentage ended at 40% in the first quarter of 2020, as compared to 42% in the first quarter of the prior year.

Operating expenses increased by $1,745 or 5% to $36,545 for the three months ended March 31, 2020, as compared to the same period in 2019. The differences in operating expenses by department are as follows:

2020 2019 Change % Change
Selling $10,474 $11,038 $(564) -5%
General and administrative 12,504 11,180 1,324 12%
Research, product development and regulatory 6,154 5,683 471 8%
Freight, delivery and warehousing 7,413 6,899 514 7%
$36,545 $34,800 $1,745 5%
  • Selling expenses decreased by $564 to end at $10,474 for the three months ended March 31, 2020, as compared to the same period of 2019. The main drivers were the favorable impact of lower foreign currency exchange rates (as they relate to operating expenses of certain foreign subsidiaries) and decreased travel costs across all of our global operating subsidiaries as a result of restrictions imposed in response to the COVID-19 pandemic.
  • General and administrative expenses increased by $1,324 to end at $12,504 for the three months ended March 31, 2020, as compared to the same period of 2019. In 2019, an adjustment was made on our deferred consideration compensation in the amount of $1,543. There was no adjustment to deferred consideration in 2020. The increase also includes foreign exchange transaction losses experienced by our foreign subsidiaries. These increases were partially offset by decreases associated with reduced incentive compensation reflecting weaker financial performance during the first three months of 2020 and from reduced travel expenses in response to the COVID-19 pandemic.
  • Research, product development costs and regulatory expenses increased by $471 to end at $6,154 for the three months ended March 31, 2020, as compared to the same period of 2019. The main drivers were increases in our product defense and product development costs relating to the commercialization of our SIMPAS delivery system.
  • Freight, delivery and warehousing costs for the three months ended March 31, 2020 were $7,413 or 7.7% of sales as compared to $6,899 or 6.9% of sales for the same period in 2019. This change is primarily driven by mix of product shipped and associated delivery destinations during the period.

Interest costs net of capitalized interest were $1,508 in the first three months of 2020, as compared to $1,612 in the same period of 2019. Interest costs are summarized in the following table:

Average Indebtedness and Interest expense

Q1 2020 Average Debt Interest Expense Interest Rate Q1 2019 Average Debt Interest Expense Interest Rate
Revolving line of credit (average) $165,076 $1,496 3.6% $143,144 $1,576 4.4%
Amortization of deferred loan fees — 59 — — 50 —
Amortization of other deferred liabilities — 3 — — — —
Other interest (income) expense — 30 — — 13 —
Subtotal $165,076 $1,588 3.8% $143,144 $1,639 4.6%
Capitalized interest — (80) — — (27) —
Total $165,076 $1,508 3.7% $143,144 $1,612 4.5%

The Company’s average overall debt for the three months ended March 31, 2020 was $165,076, as compared to $143,144 for the three months ended March 31, 2019. Our borrowings in the three months ended March 31, 2020 were higher than the same period of the prior year primarily driven by the acquisition activity over the last 12 months and the associated investment in expanded working capital. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 3.6% for the three months ended March 31, 2020, as compared to 4.4% in 2019.

Income tax expense decreased by $1,565 to end at a benefit of $205 for the three months ended March 31, 2020, as compared to income tax expense of $1,360 for the comparable period in 2019. The underlying effective tax rate for the three months ended March 31, 2020 was 31.0%. In addition, during the quarter, the Company benefited from two discrete income tax benefits. First, the Company assessed its income tax positions to account for the Coronavirus Aid Relief and Economic Security Act (“CARES Act”) which was signed into law on March 27, 2020. A provision of the act modified the amount of interest deduction allowed and therefore reduced the Company’s 2019 Global Intangible Low Tax Income (“GILTI”) inclusion. Second, the Company benefited from the tax impact of the vesting of certain stock grants. During the three months ended March 31, 2019, the Company effective tax rate was 25.7%. The effective tax rate for all interim periods is based on the projected income for the full year and is subject to ongoing review and adjustment by management.

During the three months ended March 31, 2020 and 2019 we recognized a loss of $13 and $24, respectively, on our investment in the Hong Kong joint venture which is a 50% owned equity investment.

Our overall net income for the first three months of 2020 was $520 or $0.02 per basic and diluted share, as compared to $3,906 or $0.13 per basic and diluted share in the same quarter of 2019.

LIQUIDITY AND CAPITAL RESOURCES

The Company used cash of $13,946 in operating activities during the three months ended March 31, 2020, as compared to $20,263 during the three months ended March 31, 2019. Included in the $13,946 are net income of $520, plus non-cash depreciation, amortization of intangibles and other assets and discounted future liabilities, in the amount of $5,792, and provision for bad debts in the amount of $359. Also included are stock-based compensation of $1,357, losses from equity method investment of $13, decrease in deferred income taxes of $910and net foreign currency adjustment of $823. These together provided net cash inflows of $7,954, as compared to $10,027 for the same period of 2019.

During the first three months of 2020, the Company increased working capital by $14,161, as compared to $28,358 during the same period of the prior year. Included in this change: inventories increased by $16,446 (normal at this point in the season), as compared to $23,763 for the first quarter of 2019. Deferred revenue decreased by $2,342, as compared to $16,036 in the same period of 2019, driven by customer decisions regarding demand, payment timing and our cash incentive programs. Our accounts payable balances decreased by $189, as compared to $4,788 in the same period of 2019, reflecting slower production activity this year in efforts to control inventory level. Accounts receivables increased by $5,472, as compared to a decreased of $6,812 in the same period of 2019. This is primarily driven by territorial mix of sales and some slight delays caused by COVID-19 disruption in Central America. Prepaid expenses increased by $776, as compared to $2,724 in the same period of 2019. Income tax receivable increased by $597, as compared to decreasing by $750 in the prior year. Accrued programs increased by $6,016, as compared to $2,391 in the prior year. The change reflected some changes in product mix and program strategies in US Agriculture market. Finally, other payables and accrued expenses decreased by $2,094, as compared to $2,508 in the prior year as a result of the reduced incentive compensation accrual.

With regard to our program accrual, the increase (as noted above) primarily reflects our mix of sales and customers in the first quarter of 2020, as compared to the prior year. The Company accrues programs in line with the growing season upon which specific products are targeted. Typically crop products have a growing season that ends on September 30th of each year. During the first quarter of 2020, the Company made accruals for programs in the amount of $17,189 and made payments in the amount of $11,192. During the first quarter of the prior year, the Company made accruals in the amount of $14,902 and made payments in the amount of $11,701.

Cash used for investing activities was $2,980 for the three months ended March 31, 2020, as compared to $27,615 for the three months ended March 31, 2019. The Company spent $2,980 on fixed assets acquisitions primarily focused on continuing to invest in manufacturing infrastructure.

During the three months ended March 31, 2020, financing activities provided $16,641, principally from the borrowings on the Company’s senior credit facility, as compared to $48,865 for the same period of the prior year. In the first quarter of 2020, we paid dividends to stockholders amounting to $582, as compared to $581 in the same period of 2019.

The Company has a revolving line of credit shown as long-term debt in the condensed consolidated balance sheets at March 31, 2020 and December 31, 2019. The debt is summarized in the following table:

Long-term indebtedness March 31, 2020 December 31, 2019
Revolving line of credit $168,700 $149,300
Deferred loan fees (475) (534)
Total indebtedness $168,225 $148,766

At March 31, 2020, the Company is compliant with all covenants to its Senior Credit Facility. Based on its performance against the most restrictive covenants in the Credit Agreement (see, supra Note 10), the Company had the capacity to increase its borrowings by up to $39,552, according to the terms thereof. This compares to an available borrowing capacity of $56,707 as of March 31, 2019. The level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA for both the trailing twelve month period and proforma basis arising from acquisitions, (2) net borrowings, (3) the leverage covenant (the Consolidated Funded Debt Ratio).

We believe that anticipated cash flow from operations, existing cash balances and available borrowings under our amended senior credit facility will be sufficient to provide us with liquidity necessary to fund our working capital and cash requirements for the next twelve months.

RECENTLY ISSUED ACCOUNTING GUIDANCE

Please refer to Note 15 in the accompanying Notes to the Condensed Consolidated Financial Statements for recently issued and adopted accounting standards.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The Company continually re-assesses the critical accounting policies used in preparing its financial statements. In the Company’s Form 10-K filed with the SEC for the year ended December 31, 2019, the Company provided a comprehensive statement of critical accounting policies. These policies have been reviewed in detail as part of the preparation work for this Form 10-Q. After our review of these matters, we have determined that, during the subject reporting period, there has been no material change to the critical accounting policies that are listed in the Company’s Form 10-K for the year ended December 31, 2019.

Certain of the Company’s policies require the application of judgment by management in selecting the appropriate assumptions for calculating financial estimates. These judgments are based on historical experience, terms of existing contracts, commonly accepted industry practices and other assumptions that the Company believes are reasonable under the circumstances. These estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the condensed consolidated financial statements in the period that revisions are determined to be necessary. Actual results may differ from these estimates under different outcomes or conditions.

Market risk

As filed, 1,172 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company is exposed to market risk related to changes in interest rates, primarily from its borrowing activities. The Company’s indebtedness to its primary lender is evidenced by a line of credit with a variable rate of interest, which fluctuates with changes in the lender’s reference rate. For more information, please refer to the applicable disclosures in the Company’s Form 10-K filed with the SEC for the year ended December 31, 2019.

The Company faces market risk to the extent that changes in foreign currency exchange rates affect our non-U.S. dollar functional currency as to foreign subsidiaries’ revenues, expenses, assets and liabilities. The Company currently does not engage in hedging activities with respect to such exchange rate risks.

Assets and liabilities outside the U.S. are located in regions where the Company has subsidiaries or joint ventures: Central America, South America, North America, Europe Asia, and Australia. The Company’s investments in foreign subsidiaries and joint ventures with a functional currency other than the U.S. dollar are generally considered long-term. Accordingly, the Company does not hedge these net investments.

Controls and procedures

As filed, 1,058 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

As of March 31, 2020, the Company has a comprehensive set of disclosure controls and procedures designed to ensure that all information required to be disclosed in our filings under the Securities Exchange Act (1934) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As of March 31, 2020, the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, has concluded, based on their evaluation, that the Company’s disclosure controls and procedures are effective to provide reasonable assurance of the achievement of the objectives described above.

There were no changes in the Company’s internal controls over financial reporting that occurred during the most recent quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

PART II. OTHER INFORMATION

The Company was not required to report any matters or changes for any items of Part II except as disclosed below.

Risk factors

As filed, 1,737 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company continually re-assesses the business risks, and as part of that process detailed a range of risk factors in the disclosures in American Vanguard’s Report on Form 10-K for the fiscal year ended December 31, 2019, filed on March 10, 2020. In preparing this document, we have reviewed all the risk factors included in that document and find that there are no material changes to those risk factors, except for the following:

The Covid-19 pandemic is creating risk, uncertainty and adverse conditions in many industries both here and abroad. The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business, including how the pandemic will impact its customers, business partners, and employees. While the Company did not incur significant disruptions from the COVID-19 pandemic during the three months ended March 31, 2020, the Company is unable to predict the impact that the pandemic will have on its financial condition, results of operations and cash flows due to numerous uncertainties. The extent to which the COVID-19 pandemic impacts the Company’s operations and those of its customers will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the scope, severity and duration of the pandemic, the actions taken to contain the pandemic or mitigate its impact, and the direct and indirect economic effects of the pandemic and containment measures, among others. There is no guarantee that the Company will be able to operate without material disruption for the duration of the pandemic or that its financial conditions and results of operations will not be materially adversely affected by the pandemic in future quarters.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2020-01-01 to 2020-03-31$96.0mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2020-01-01 to 2020-03-31$57.6mus-gaap:CostOfRevenue
Gross profit3 months2020-01-01 to 2020-03-31$38.4mus-gaap:GrossProfit
Operating income3 months2020-01-01 to 2020-03-31$1.8mus-gaap:OperatingIncomeLoss
Interest expense3 months2020-01-01 to 2020-03-31$1.5mus-gaap:InterestExpense
Income tax3 months2020-01-01 to 2020-03-31−$205.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2020-01-01 to 2020-03-31$520.0kus-gaap:NetIncomeLoss
Diluted EPS3 months2020-01-01 to 2020-03-31$0.02us-gaap:EarningsPerShareDiluted
Basic EPS3 months2020-01-01 to 2020-03-31$0.02us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2020-01-01 to 2020-03-3129,948,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2020-01-01 to 2020-03-31−$13.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Dividends paid3 months2020-01-01 to 2020-03-31$582.0kus-gaap:PaymentsOfDividends
Cash and equivalentsAt period end2020-03-31$5.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-03-31$350.6mus-gaap:AssetsCurrent
Total assetsAt period end2020-03-31$674.2mus-gaap:Assets
Current liabilitiesAt period end2020-03-31$139.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-03-31$340.0mus-gaap:Liabilities
Long-term debtAt period end2020-03-31$168.2mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2020-03-31$334.2mus-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Source: SEC EDGAR, the filing index for accession 0001564590-20-024220. Last ingested by Listed: Nov 11, 2026, 00:16 ET. Listed shows no prices and gives no investment advice.